Hostname: page-component-797576ffbb-xmkxb Total loading time: 0 Render date: 2023-12-03T13:28:51.156Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "useRatesEcommerce": true } hasContentIssue false
  • English
  • Français

Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer’s disease subjects

Published online by Cambridge University Press:  10 April 2015

Paul L. Wood ,
Brooke L. Barnette ,
Jeffrey A. Kaye ,
Joseph F. Quinn  and
Randall L. Woltjer
Paul L. Wood*
Affiliation:
Metabolomics Unit, Department of Physiology and Pharmacology, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Harrogate, TN, USA
Brooke L. Barnette
Affiliation:
Metabolomics Unit, Department of Physiology and Pharmacology, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Harrogate, TN, USA
Jeffrey A. Kaye
Affiliation:
Department of Neurology, Portland VA Medical Center, Oregon Health Science University, Portland, OR, USA
Joseph F. Quinn
Affiliation:
Department of Neurology, Portland VA Medical Center, Oregon Health Science University, Portland, OR, USA
Randall L. Woltjer
Affiliation:
Department of Neurology, Portland VA Medical Center, Oregon Health Science University, Portland, OR, USA
*
Paul L. Wood, Metabolomics Unit, Department of Physiology and Pharmacology, DeBusk College of Osteopathic Medicine, Lincoln Memorial University, 6965 Cumberland Gap Parkway, Harrogate, TN 37752, USA Tel: 423-869-6666; Fax: 423-869-7174; E-mail: paul.wood@lmunet.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

We undertook a non-targeted lipidomics analysis of post-mortem cerebrospinal fluid (CSF), frontal cortex grey matter, and subjacent white matter to define potential biomarkers that distinguish cognitively intact subjects from those with incipient or established dementia. Our objective was to increase our understanding of the role of brain lipids in pathophysiology of aging and age-related cognitive impairment.

Methods

Levels of 650 individual lipids, across 26 lipid subclasses, were measured utilising a high-resolution mass spectrometric analysis platform.

Results

Monoacylglycerols (MAG), diacylglycerols (DAG), and the very-long-chain fatty acid 26:0 were elevated in the grey matter of the mild cognitive impairment (MCI) and old dementia (OD) cohorts. Ethanolamine plasmalogens (PlsEtn) were decreased in the grey matter of the young dementia (YD) and OD cohorts while and phosphatidylethanolamines (PtdEth) were lower in the MCI, YD and OD cohorts. In the white matter, decrements in sulphatide levels were detected in the YD group, DAG levels were elevated in the MCI group, and MAG levels were increased in the YD and OD groups.

Conclusion

The parallel changes in grey matter MAGs and DAGs in the MCI and OD groups suggest that these two cohorts may have a similar underlying pathophysiology; consistent with this, MCI subjects were more similar in age to OD than to YD subjects. While PlsEtn and phosphatidylethanolamine were decreased in the YD and OD groups they were unaltered in the MCI group indicating that alterations in plasmalogen synthesis are unlikely to represent an initiating event in the transition from MCI to dementia.

Keywords

Alzheimer’s diseaselipidomicsdiacylglycerolsmild cognitive impairmentfrontal cortex
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 27 , Issue 5 , October 2015 , pp. 270 - 278
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Korczyn, AD. The amyloid cascade hypothesis. Alzheimers Dement 2008;4:176–178.Google Scholar
2. Castello, MA, Soriano, S. On the origin of Alzheimer’s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev 2013;13C:10–12.Google Scholar
3. Farlow, MR, Brosch, JR. Immunotherapy for Alzheimer’s disease. Neurol Clin 2013;31:869–878.Google Scholar
4. Schneider, JA, Arvanitakis, Z, Bang, W, Bennett, DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–2204.Google Scholar
5. Ganguli, M, Rodriguez, E. Age, Alzheimer’s disease, and the big picture. Int Psychogeriatr 2011;23:1531–1534.Google Scholar
6. Erten-Lyons, D, Woltjer, R, Kaye, J et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013;81:977–983.Google Scholar
7. Maarouf, CL, Daugs, ID, Kokjohn, TA et al. Alzheimer’s disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One 2011;6:e27291.Google Scholar
8. Kramer, PL, Xu, H, Woltjer, RL et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging 2011;32:2113–2122.Google Scholar
9. Jellinger, KA. Alzheimer’s changes in non-demented and demented patients. Acta Neuropathol 1995;89:112–113.Google Scholar
10. Erten-Lyons, D, Woltjer, RL, Dodge, H et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354–360.Google Scholar
11. Wood, PL. Lipidomics of Alzheimer’s disease: current status. Alzheimers Res Ther 2012;4:5.Google Scholar
12. Ginsberg, L, Rafique, S, Xuereb, JH, Rapoport, SI, Gershfeld, NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res 1995;698:223–226.Google Scholar
13. Han, X, Holtzman, DM, McKeel, DW Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001;77:1168–1180.Google Scholar
14. Kou, J, Kovacs, GG, Höftberger, R et al. Peroxisomal alterations in Alzheimer’s disease. Acta Neuropathol 2011;122:271–283.Google Scholar
15. Chan, RB, Oliveira, TG, Cortes, EP et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 2012;287:2678–2688.Google Scholar
16. Cutler, RG, Kelly, J, Storie, K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Nat Acad Sci U.S.A 2004;101:2070–2075.Google Scholar
17. Han, X, Holtzman, DM, McKeel, DW Jr., Kelley, J, Morris, JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J Neurochem 2002;82:809–818.Google Scholar
18. Schuhmann, K, Almeida, R, Baumert, M, Herzog, R, Bornstein, SR, Shevchenko, A. Shotgun lipidomics on a LTQ Orbitrap mass spectrometer by successive switching between acquisition polarity modes. J Mass Spectrom 2012;47:96–104.Google Scholar
19. Wood, PL, Shirley, NR. Lipidomics analysis of postmortem interval: preliminary evaluation of human skeletal muscle. Metabolomics 2013;3:3.Google Scholar
20. Wood, PL, Filiou, MD, Otte, DM, Zimmer, A, Turck, CW. Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72/G30 transgenic mouse. Schizophrenia Res 2014;159:365–369.Google Scholar
21. Cheng, H, Wang, M, Li, JL, Cairns, NJ, Han, X. Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer’s disease: an early event in disease pathogenesis. J Neurochem 2013;127:733–738.Google Scholar
22. Shimohama, S, Sasaki, Y, Fujimoto, S et al. Phospholipase C isozymes in the human brain and their changes in Alzheimer’s disease. Neuroscience 1998;82:999–1007.Google Scholar
23. Zhang, D, Dhillon, H, Prasad, MR, Markesbery, WR. Regional levels of brain phospholipase Cgamma in Alzheimer’s disease. Brain Res 1998;811:161–165.Google Scholar
24. Wood, PL, Phillipps, A, Woltjer, RL, Kaye, JA, Quinn, JF. Increased lysophosphatidylethanolamine and diacylglycerol levels in Alzheimer’s disease plasma. JSM Alzheimer’s Dis Relat Demen 2014;1:1001.Google Scholar
25. González-Domínguez, R, García-Barrera, T, Gómez-Ariza, JL. Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer’s disease. Talanta 2015;131:480–489.Google Scholar
26. Carrasco, S, Mérida, I. Diacylglycerol, when simplicity becomes complex. Trends Biochem Sci 2007;32:27–36.Google Scholar
27. Farooqui, AA, Liss, L, Horrocks, LA. Stimulation of lipolytic enzymes in Alzheimer’s disease. Ann Neurol 1988;23:306–308.Google Scholar
28. Mulder, J, Zilberter, M, Pasquaré, SJ et al. Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain 2011;134:1041–1060.Google Scholar
29. Gulyas, AI, Cravatt, BF, Bracey, MH et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004;20:441–458.Google Scholar
30. Savinainen, JR, Saario, SM, Laitinen, JT. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) 2012;204:267–276.Google Scholar
31. Paula-Lima, AC, Brito-Moreira, J, Ferreira, ST. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer’s disease. J Neurochem 2013;126:191–202.Google Scholar
32. Wood, PL. Alzheimer’s disease: status of the neuroinflammatory hypothesis. Curr Res Alzheimer’s Dis 1998;3:1–8.Google Scholar
33. Anderson, CM, Stahl, A. SLC27 fatty acid transport proteins. Mol Aspects Med 2013;34:516–528.Google Scholar
34. Quinn, JF, Raman, R, Thomas, RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903–1911.Google Scholar
35. Bjorklund, NL, Reese, LC, Sadagoparamanujam, VM, Ghirardi, V, Woltjer, RL, Taglialatela, G. Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology. Mol Neurodegener 2012;7:23.Google Scholar
36. Wood, PL, Wood, JA. Critical assessment of the status of Alzheimer’s disease biomarkers. J Parkinson’s Dis Alzheimer’s Dis 2014;1:4.Google Scholar